問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Veterans General Hosptial

Recruiting

List

116Cases

2016-09-01 - 2021-11-30

Phase III

A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected Treatment-naïve Adults adults

  • Condition/Disease

    Infection, Human Immunodeficiency Virus HIV Infections

  • Test Drug

    Dolutegravir(DTG),Lamivudine(3TC).Tenofovir(TDF )/emtricitabine(FTC)

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2021-11-01 - 2029-04-23

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-11-19 - 2024-12-31

Phase III

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

  • Condition/Disease

    Chronic Kidney Disease With Metabolic Acidosis

  • Test Drug

    TRC101

Participate Sites
12Sites

Recruiting11Sites

Terminated1Sites

2019-09-11 - 2023-07-06

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults

  • Condition/Disease

    HIV-1 and Hepatitis B Co-Infection

  • Test Drug

    Biktarvy

Participate Sites
9Sites

Recruiting6Sites

Terminated3Sites

2022-10-05 - 2024-02-12

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-04-19 - 2024-03-21

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-10-29 - 2021-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2013-01-01 - 2022-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2018-03-01 - 2022-08-31

Phase III

A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF CARE ANTICOAGULANT THERAPY IN PEDIATRIC SUBJECTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE WITH CONFIRMED VENOUS THROMBOEMBOLISM (VTE)

  • Condition/Disease

    Venous thromboembolism

  • Test Drug

    Edoxaban

Participate Sites
5Sites

Recruiting5Sites

2019-09-20 - 2022-12-31

Phase II

A Phase 2A, 2-Part Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Ceftazidime and Avibactam in Neonates and Infants From Birth to Less Than 3 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment

  • Condition/Disease

    Gram-negative Bacterial Infection

  • Test Drug

    ceftazidime-avibactam

Participate Sites
7Sites

Recruiting7Sites

1 8 9 10 11 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB